In-vivo Bioequivalence Study of Ranolazine 500 mg extended-release tablets (Arang Pharma, Iran)
Not Applicable
Recruiting
- Conditions
- This study is performed on healthy volunteers and drug concentration in plasma is determined..
- Registration Number
- IRCT20200105046010N103
- Lead Sponsor
- Arang Pharm Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (Liver, Heart, and Kidney)
Body Mass Index (18-28) kg/m^2
Informed consent
Informed consentAge (18-55 years old)
Exclusion Criteria
Nicotine consumption
historyCardiovascular disease
disease HistoryLiver and kidney disease
HistoryAlcohol and opioid addiction
Allergy reactions history to Linagliptin or Metformin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method